Category Archives: Blog

Frontida BioPharm, Inc. Names Dr. Ralph Landau President

Frontida BioPharm, Inc. Names Dr. Ralph Landau President

Frontida Biopharm, Inc is pleased to announce that Dr. Ralph Landau has been appointed to the role of President of Frontida Biopharm, Inc. He will be responsible the operations in both the United States and China.

Frontida acquires from Sun

Frontida BioPharm acquires Philadelphia & Aurora facilities from Sun Pharmaceuticals

Philadelphia, PA – June 4, 2016: Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, today announced that its affiliate company, Frontida BioPharm, Inc. (“Frontida”) has acquired certain assets from a wholly owned US subsidiary of Sun Pharma.

AdaptDose™ an Innovative platform

AdaptDose™, The innovation in drug development, that reduces development time by up to 30%

Frontida’s AdaptDose™ technology platform provides a tool that can eliminate the need to reformulate after Phase I and overcomes several technical hurdles in the development and scale up of (1) new molecules, (2) binary and tertiary mixtures of active ingredients, zero and first order drug release matrices, or (3) scalable clinical trial materials used in dose ranging or adaptive dose clinical studies.

Warning Letter Closure

FDA Warning Letter Closure

Frontida BioPharm, Inc. a Contract Development and Manufacturing Organization located in Philadelphia, PA and Aurora, IL announces that the Food and Drug Administration (“FDA”) has issued a closure letter for its Philadelphia manufacturing site on May 4, 2017.

Frontida BioPharm and TruPharma Finalize Partnership For Marketing of 5 Products

Frontida BioPharm and TruPharma Finalize Partnership For Marketing of 5 Products

Frontida BioPharm, Inc. a Contract Development and Manufacturing Organization with headquarters in Philadelphia, PA announced that it has entered into an exclusive agreement with TruPharma, LLC to market and distribute five ANDAs.